Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eyenovia, Inc. (EYEN) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as it transitions to operating under the name Hyperion DeFi, Inc. These filings include Current Reports on Form 8-K that describe material events such as the corporate name change from Eyenovia, Inc. to Hyperion DeFi, Inc., the anticipated Nasdaq ticker change from EYEN to HYPD, and the launch of a new cryptocurrency treasury strategy focused on the HYPE token native to the Hyperliquid blockchain.
In its 8-K filings, the company supplements its business description and risk factors to explain its dual focus on digital ophthalmic technology and building a long-term strategic treasury of HYPE. Investors can review details of the private placement used to fund HYPE acquisitions, the structure of preferred stock and warrants issued in that transaction, and amendments to loan agreements that adjust maturity dates, interest rates and related warrant grants. These documents also outline the company’s plan to implement a HYPE staking program and operate a co-branded validator on Hyperliquid.
Filings further describe the Optejet User Filled Device (UFD), including its intended use with various topical ophthalmic liquids and its role in the company’s ophthalmic business. Risk factor disclosures address potential volatility in the price of HYPE, regulatory and market risks associated with digital assets, and other considerations that may affect the company’s financial condition and share price.
On Stock Titan, users can access these SEC filings as they are made available through EDGAR, along with AI-powered summaries that highlight key points from 8-Ks and other reports. This helps readers quickly understand how corporate actions, financing arrangements, digital asset strategies and device development updates are reflected in Eyenovia’s official regulatory record under the EYEN symbol and its subsequent Hyperion DeFi, Inc. identity.
Hyperion DeFi, Inc. will hold its 2025 virtual Annual Meeting on 18 Aug 2025 at 12:00 PM EDT. Stockholders of record as of 18 Jul 2025 will vote on nine items.
- Proposal 1–3: elect five directors, ratify new auditor CBIZ CPAs P.C., and cast a say-on-pay advisory vote.
- Proposal 4: double authorized common stock to 600 million and preferred stock to 60 million. As of 8 Jul 2025 only 244.1 million common and 0.56 million preferred shares remain unissued; the board cites financing flexibility as the main reason.
- Proposal 5: amend the charter to allow stockholders to act by written consent.
- Proposal 6: add 5.3 million shares to the 2018 Omnibus Stock Incentive Plan, raising its pool to 5.73 million shares; just 27,186 shares remain currently.
- Proposal 7: approve issuance of up to 394,236 shares upon warrant exercise under Nasdaq Rule 5635(d).
- Proposal 8: authorize adjournment to solicit more votes if Proposals 4, 5, or 7 lack support.
The proxy discloses a recent auditor transition—Marcum LLP resigned on 2 May 2025 after its attest practice was acquired by CBIZ. Marcum’s 2023–24 reports contained a going-concern paragraph and identified two material weaknesses, which management is addressing.
The charter amendments give the board wide latitude to issue a large number of new shares, potentially introducing dilution risk but also enabling capital raises, M&A and employee incentives. Governance rights improve slightly through the proposed written-consent provision and annual director elections.
Eyenovia, Inc. (Nasdaq: EYEN) has filed a Prospectus Supplement under Form 424B5 to update its existing at-the-market (ATM) equity program with Chardan Capital Markets. The filing registers the offer and sale of up to $14,942,887 in additional common stock, a figure calculated to comply with General Instruction I.B.6 of Form S-3.
• As of 27 June 2025, the company’s non-affiliate public float was approximately $52.8 million, based on 4,853,092 shares at $10.88 per share.
• I.B.6 limits primary offerings to one-third of that float—about $17.6 million—within any 12-month period when the float is under $75 million.
• Eyenovia has already sold $2.66 million of securities during the preceding 12 months, leaving capacity for the newly registered $14.94 million.
The filing does not alter the total $50 million ceiling of the December 30, 2024 amended Sales Agreement, but it refreshes the amount currently eligible for issuance. Shares will be sold from time to time through Chardan acting as sales agent, at market prices on Nasdaq Capital Market under the symbol EYEN.
The supplement reiterates that investment in EYEN entails a high degree of risk and directs investors to previously filed risk factors in the company’s 10-K and 8-K dated 27 June 2025.
FAQ
What is the current stock price of Eyenovia (EYEN)?
What is the market cap of Eyenovia (EYEN)?
